| Allosteric activators of glucokinase: potential role in diabetes therapy J Grimsby, R Sarabu, WL Corbett, NE Haynes, FT Bizzarro, JW Coffey, ... Science 301 (5631), 370-373, 2003 | 629 | 2003 |
| Glucokinase activators for diabetes therapy: May 2010 status report FM Matschinsky, B Zelent, N Doliba, C Li, JM Vanderkooi, A Naji, ... Diabetes Care 34 (Suppl 2), S236, 2011 | 132 | 2011 |
| A regiocontrolled synthesis of N7-and N9-guanine nucleosides P Garner, S Ramakanth The Journal of Organic Chemistry 53 (6), 1294-1298, 1988 | 128 | 1988 |
| Stereodivergent synthesis of threo and erythro 6-amino-6-deoxyheptosulose derivatives via an optically active oxazolidine aldehyde P Garner, S Ramakanth The Journal of Organic Chemistry 51 (13), 2609-2612, 1986 | 128 | 1986 |
| Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure− activity relationships, and x-ray crystal structures DR Bolin, AL Swain, R Sarabu, SJ Berthel, P Gillespie, NJS Huby, ... Journal of medicinal chemistry 43 (11), 2135-2148, 2000 | 115 | 2000 |
| Discovery of piragliatin first glucokinase activator studied in type 2 diabetic patients R Sarabu, FT Bizzarro, WL Corbett, MT Dvorozniak, W Geng, JF Grippo, ... Journal of medicinal chemistry 55 (16), 7021-7036, 2012 | 109 | 2012 |
| Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics NM Doliba, W Qin, H Najafi, C Liu, CW Buettger, J Sotiris, HW Collins, ... American Journal of Physiology-Endocrinology and Metabolism 302 (1), E87-E102, 2012 | 105 | 2012 |
| Targeting glucokinase activation for the treatment of type 2 diabetes--a status review. R Sarabu, J Grimsby Current opinion in drug discovery & development 8 (5), 631-637, 2005 | 89 | 2005 |
| DPP IV inhibitors M Boehringer, D Hunziker, H Kuehne, BM Loeffler, R Sarabu, HP Wessel US Patent 6,861,440, 2005 | 78 | 2005 |
| Heteroaromatic glucokinase activators FT Bizzarro, WL Corbett, JF Grippo, NE Haynes, GW Holland, RF Kester, ... US Patent 6,320,050, 2001 | 77 | 2001 |
| Glucokinase activators as new type 2 diabetes therapeutic agents R Sarabu, SJ Berthel, RF Kester, JW Tilley Expert Opinion on Therapeutic Patents 18 (7), 759-768, 2008 | 76 | 2008 |
| Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules F Falcioni, K Ito, D Vidovic, C Belunis, R Campbell, SJ Berthel, DR Bolin, ... Nature biotechnology 17 (6), 562-567, 1999 | 71 | 1999 |
| Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects FM Matschinsky, B Zelent, NM Doliba, KH Kaestner, JM Vanderkooi, ... Diabetes-Perspectives in Drug Therapy, 357-401, 2011 | 68 | 2011 |
| Glucokinase activators for the potential treatment of type 2 diabetes J Grimsby, SJ Berthel, R Sarabu Current topics in medicinal chemistry 8 (17), 1524-1532, 2008 | 68 | 2008 |
| Novel glucokinase activators: a patent review (2008–2010) R Sarabu, SJ Berthel, RF Kester, JW Tilley Expert opinion on therapeutic patents 21 (1), 13-33, 2011 | 67 | 2011 |
| Heteroaromatic glucokinase activators FT Bizzarro, WL Corbett, JF Grippo, NE Haynes, GW Holland, RF Kester, ... US Patent 6,951,945, 2005 | 65 | 2005 |
| Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2R)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2 … NE Haynes, WL Corbett, FT Bizzarro, KR Guertin, DW Hilliard, ... Journal of medicinal chemistry 53 (9), 3618-3625, 2010 | 61 | 2010 |
| Heteroaromatic glucokinase activators FT Bizzarro, WL Corbett, JF Grippo, NE Haynes, GW Holland, RF Kester, ... US Patent 6,610,846, 2003 | 61 | 2003 |
| Fused heteroaromatic glucokinase activators WL Corbett, JS Grimsby, NE Haynes, RF Kester, PE Mahaney, R Sarabu US Patent 6,448,399, 2002 | 60 | 2002 |
| Preparation of carboalkoxyalkylphenylalanine derivatives from tyrosine JW Tilley, R Sarabu, R Wagner, K Mulkerins The Journal of Organic Chemistry 55 (3), 906-910, 1990 | 60 | 1990 |
